2-AG, 2-arachidonylglycerol; 2D, two-dimensional; AEA, Anandamide; ANP, Atrial Natriuretic Peptide; ASE, the American Society of Echocardiography; AUC, area under the curve; BA, bile acid; BNP, Brain natriuretic peptide; CAD, coronary artery disease; CB-1, cannabinoid −1; CCM, Cirrhotic Cardiomyopathy; CMR, cardiovascular magnetic resonance imaging; CO, cardiac output; CT, computed tomography; CTP, Child­Turcotte­Pugh; CVP, central venous pressure; DT, deceleration Time; ECG, electrocardiogram; ECV, extracellular volume; EF, Ejection fraction; EMD, electromechanical desynchrony; ESLD, end-stage liver disease; FXR, Farnesoid X receptor; GI, gastrointestinal; GLS, Global Longitudinal strain; HCN, Hyperpolarization-activated cyclic nucleotide­gated; HE, hepatic encephalopathy; HF, heart failure; HO, Heme oxygenase; HPS, hepatopulmonary syndrome; HR, heart rate; HRS, hepatorenal syndrome; HVPG, hepatic venous pressure gradient; HfmrEF, heart failure with mid-range ejection fraction; HfrEF, heart failure with reduced ejection fraction; IVC, Inferior Vena Cava; IVCD, IVC Diameter; IVS, intravascular volume status; L-NAME, NG-nitro-L-arginine methyl ester; LA, left atrium; LAVI, LA volume index; LGE, late gadolinium enhancement; LT, liver transplant; LV, left ventricle; LVDD, left ventricular diastolic dysfunction; LVEDP, left ventricular end-diastolic pressure; LVEDV, LV end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, LV end systolic volume; LVOT, left ventricular outflow tract; MAP, mean arterial pressure; MELD, Model for End-Stage Liver Disease; MR, mitral regurgitation; MRI, Magnetic resonance imaging; MV, mitral valve; NAFLD, Nonalcoholic fatty liver disease; NO, nitric oxide; NOS, Nitric oxide synthases; NTProBNP, N-terminal proBNP; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedged pressure; PHT, portal hypertension; PWD, Pulsed-wave Doppler; RV, right ventricle; RVOT, right ventricular outflow tract; SA, sinoatrial; SD, standard deviation; SV, stroke volume; SVR, Systemic vascular resistance; TDI, tissue Doppler imaging; TIPS, transjugular intrahepatic portosystemic shunt; TR, Tricuspid valve; TRPV1, transient receptor potential cation channel subfamily V member 1; TTE, transthoracic echocardiography; USG, ultrasonography; VTI, velocity time integral; beta blocker; cirrhotic cardiomyopathy; hemodynamics in cirrhosis; left ventricular diastolic dysfunction